Tuberculosis vaccine H56IC - Valneva/AJ Vaccines

Drug Profile

Tuberculosis vaccine H56IC - Valneva/AJ Vaccines

Alternative Names: Adjuvanted TB subunit vaccine H56IC - Valneva/AJ Vaccines; AERAS-456; Ag85B-ESAT-6-Rv2660-IC31; H56; H56/AERAS-456 + IC31; H56/IC31 vaccine; H56: IC31; H56IC; TB-vaccine-H56IC--Intercell/Statens-Serum-Institut; Tuberculosis-vaccine-H56IC-Intercell/Statens-Serum-Institut

Latest Information Update: 10 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Statens Serum Institut
  • Developer Aeras; AJ Vaccines; Statens Serum Institut
  • Class Adjuvants; Antituberculars; Recombinant fusion proteins; Subunit vaccines; Synthetic vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 04 May 2017 Aeras plans a phase II trial for Tuberculosis (Prevention, In volunteers, In children, In adolescents) in South Africa and Tanzania (PACTR201704002006214)
  • 16 Jan 2017 Statens Serum Institut sold its vaccine production business to AJ Vaccines
  • 09 Dec 2016 Aeras completes a phase Ib trial for Tuberculosis (In volunteers) in South Africa (NCT02378207)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top